SeQuent Scientific Ltd
NSE:SEQUENT
SeQuent Scientific Ltd
Research & Development
SeQuent Scientific Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
SeQuent Scientific Ltd
NSE:SEQUENT
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Lupin Ltd
NSE:LUPIN
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
SeQuent Scientific Ltd
Glance View
SeQuent Scientific Ltd. manufactures and produces veterinary pharmaceuticals and specialty chemicals. The company is headquartered in Bangalore, Karnataka. The company went IPO on 2016-03-10. The firm operates in the domains of animal health, in which it provides active pharmaceutical ingredient (APIs) and finished dosage formulations, and analytical services. The firm through its subsidiary, Alivira Animal Health Limited, offers APIs and formulations. Alivira Animal Health Limited has manufacturing facilities in five countries, including India. The Company’s subsidiary, Sequent Research Limited, is a contract research organization, which is engaged in analytical and biological analytical services to support the API, pharmaceutical, personal care and nutraceutical companies. Sequent Research Limited provides complete analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopeial monographs, customer-developed methods or in-house method development.